Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch | Zendy

Raymund R. Razonable | Zendy; John C. O’Horo | Zendy; Sara N. Hanson | Zendy; Richard Arndt | Zendy; Leigh L. Speicher | Zendy; Teresa A Seville | Zendy; Scott T. Hall | Zendy; Marsha L. Pike | Zendy; Alexander Heyliger | Zendy; Jennifer J. Larsen | Zendy; Ravindra Ganesh | Zendy; Sidna M. TulledgeScheitel | Zendy

Open Access

Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch

Author(s) -

Raymund R. Razonable,

John C. O’Horo,

Sara N. Hanson,

Richard Arndt,

Leigh L. Speicher,

Teresa A Seville,

Scott T. Hall,

Marsha L. Pike,

Alexander Heyliger,

Jennifer J. Larsen,

Ravindra Ganesh,

Sidna M. TulledgeScheitel

Publication year - 2022

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jiac346

Subject(s) - ritonavir , medicine , confidence interval , epoch (astronomy) , covid-19 , retrospective cohort study , disease , virology , virus , viral load , infectious disease (medical specialty) , stars , physics , astronomy , antiretroviral therapy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research